HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cosmair

This article was originally published in The Rose Sheet

Executive Summary

Lancome Vitalite Douceur body care collection comprises three new products -- Douceur Pure Cleansing Body Milk, Gommage Pur Exfoliating Body Gel and Energibuste Firming-Toning Bust Treatment; two reformulated and repackaged products -- Savon Fraichelle Invigorating Body Cleansing Gel and Exfoliant Fraichelle invigorating Body Scrub; and two existing products -- Stimulative Dual Action Body Creme and Hydra-Balance Essential Hydrating Body Lotion. All of the items contain magnesium, which combats free radicals; essential fatty acids, said to "contribute to a sort, supple and radiant skin"; and provitamin B[5], which encourages moisture recovery, according to the firm. The new and existing items will be presented together under the Vitalite Douceur name beginning in April. Suggested retail prices for the products range from $20 for a 6.8 oz. tube of Savon Fraichelle to a 6.8 oz. jar of Stimulative Dual Action Body Creme

You may also be interested in...



Strides Targets $200-400m From Generic Injectables In Mid-Term

Strides has set a sales target of $200-400m for Stelis’s generic injectables business in two to four years as part of its plan to reach $800m in total revenues in four years. Meanwhile, Stelis’s Rh-teriparatide for osteoporosis and sodium hyaluronate for osteoarthritis await Phase III incremental studies in the US.

Abbott Readying Vildagliptin ER In India Amid Price Competition

Abbott is developing an extended release version of vildagliptin in India, adding a new dimension to the market dynamics for the DPP-4 inhibitor, which has seen a key patent expire. Sustained release vildagliptin products from Wockhardt and Synokem also appear to be in the works.

AstraZeneca's Risky Lynparza Endpoint In Pancreatic Cancer Goes Before Advisory Cmte.

US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.

Topics

UsernamePublicRestriction

Register

RS000141

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel